New cancer drug AMG 256 tested for safety in 34 patients

NCT ID NCT04362748

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This early-stage study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The study is now complete, but it does not offer a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Cliniques Universitaires Saint Luc

    Brussels, 1200, Belgium

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Catalonia, 08036, Spain

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, 08035, Spain

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • St Vincents Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • Universitair Ziekenhuis Gent

    Ghent, 9000, Belgium

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Washington University

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.